What Is 10x Genomics

Overview

10x Genomics is a leading biotechnology company specializing in high-throughput genomic analysis technologies, particularly in the field of single-cell sequencing. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company is headquartered in Pleasanton, California. Its mission is to accelerate scientific discovery by enabling researchers to analyze biological systems at unprecedented resolution through scalable, innovative tools.

The company emerged during a transformative period in genomics, following the completion of the Human Genome Project and the rapid decline in DNA sequencing costs. Recognizing a bottleneck in data interpretation due to bulk sequencing methods, 10x Genomics focused on developing technologies that could resolve cellular heterogeneity. Their breakthrough came with the Chromium platform, launched in 2016, which allowed scientists to profile thousands of individual cells simultaneously—revolutionizing fields like immunology, oncology, and neuroscience.

10x Genomics has become a key player in the life sciences industry, contributing to major research initiatives such as the Human Cell Atlas and COVID-19 host response studies. Its instruments and reagents are used in academic, clinical, and pharmaceutical research labs across more than 50 countries. The company’s impact is underscored by its rapid growth and its 2019 initial public offering (IPO), which valued it at over $2 billion and solidified its status as a genomics innovator.

How It Works

The core innovation behind 10x Genomics lies in its ability to isolate and barcode individual cells for high-throughput sequencing. The process begins with a tissue or cell suspension, which is partitioned into nanoliter-scale droplets using microfluidics. Each droplet contains a single cell, a hydrogel bead embedded with unique DNA barcodes, and reagents for reverse transcription or library preparation. This enables parallel processing of tens of thousands of cells in a single run.

• Single-Cell Partitioning: Cells are encapsulated into droplets using microfluidic chips, ensuring one cell per droplet to prevent cross-contamination. This allows for the analysis of up to 10,000–80,000 cells per run, depending on the assay.
• Barcoded Beads (GEMs): Gel Beads in Emulsion (GEMs) carry oligonucleotides with unique molecular identifiers (UMIs) and cell barcodes. These tag RNA or DNA from each cell, enabling computational reconstruction of single-cell data after sequencing.
• Reverse Transcription: Inside each droplet, mRNA from the cell is reverse-transcribed into cDNA with attached barcodes. This preserves cell identity and transcript origin, allowing for gene expression profiling.
• Library Preparation: After droplet breaking, barcoded cDNA is amplified and prepared for next-generation sequencing (NGS). The resulting libraries are sequenced on platforms like Illumina.
• Chromium Controller: This automated instrument handles droplet generation, mixing, and partitioning, reducing manual error and increasing reproducibility across experiments.
• Cell Ranger Software: 10x provides a bioinformatics pipeline called Cell Ranger that processes raw sequencing data into gene-cell matrices, performs clustering, and enables visualization of cell types.
• Multiome Technology: The company also offers assays that combine single-cell RNA sequencing with ATAC-seq (chromatin accessibility), allowing integrated analysis of gene expression and regulatory elements in the same cell.

Key Details and Comparisons

The comparison highlights 10x Genomics’ competitive edge in scalability and integration. While Smart-seq2 offers superior sensitivity per cell, it is low-throughput and labor-intensive. In contrast, 10x Genomics strikes a balance between throughput and data quality, making it ideal for large-scale studies. Its proprietary microfluidic system and end-to-end workflow—from sample to insight—reduce variability and increase reproducibility. Furthermore, its multi-modal assays, such as Single Cell Multiome ATAC + Gene Expression, allow researchers to correlate gene regulation with expression, a capability unmatched by most competitors. This integration has made 10x Genomics the preferred choice for consortium projects like the Human Tumor Atlas Network.

Real-World Examples

10x Genomics technologies have been instrumental in advancing biomedical research. During the COVID-19 pandemic, researchers used the Chromium platform to profile immune responses in infected patients, identifying key cell types involved in severe disease. A landmark study published in Nature in 2020 analyzed over 100,000 immune cells from critically ill patients, revealing a dysregulated interferon response and exhausted T-cell phenotypes—insights that informed therapeutic development.

Another major application is in cancer research, where 10x Genomics has enabled the dissection of tumor microenvironments. For example, scientists at the Parker Institute for Cancer Immunotherapy used single-cell RNA sequencing to map immune cell infiltration in melanoma, leading to the discovery of novel checkpoint targets. These findings are accelerating the development of personalized immunotherapies.

1. Human Cell Atlas: 10x Genomics is a core technology provider, helping to map all human cell types using single-cell transcriptomics.
2. PsychENCODE Project: Used to study gene regulation in schizophrenia and autism at single-cell resolution.
3. Allen Brain Atlas: Enabled detailed mapping of neuronal subtypes in the human brain.
4. 100,000 Genomes Project: Integrated spatial genomics to study rare diseases and cancer.

Why It Matters

10x Genomics has fundamentally transformed how scientists study biological systems. By enabling high-resolution analysis of individual cells, it has moved genomics beyond bulk averages into a realm where rare cell populations, transient states, and complex interactions can be deciphered. This shift is critical for understanding diseases like cancer, autoimmune disorders, and neurodegenerative conditions, where cellular heterogeneity plays a central role.

• Impact: Enabled the discovery of previously unknown cell types, such as novel immune subsets in lung tissue.
• Therapeutic Development: Accelerated drug discovery by identifying precise cellular targets in diseases like rheumatoid arthritis.
• Clinical Diagnostics: Paving the way for single-cell-based diagnostics in oncology and prenatal testing.
• Data Standardization: Provided consistent, reproducible workflows adopted by major consortia worldwide.
• Economic Growth: Created over 1,000 high-tech jobs and spurred investment in the biotech sector.

As genomic medicine evolves, the ability to resolve biological complexity at the single-cell level will become increasingly essential. 10x Genomics continues to innovate, recently launching Xenium, a spatial gene expression platform that maps RNA within tissue architecture. With its expanding portfolio and global reach, the company remains at the forefront of the genomics revolution, driving discoveries that could one day lead to cures for some of humanity’s most challenging diseases.